Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 27, 2012, Pages 10966-10971

  Li, Fubin ^a   Ravetch, Jeffrey V ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Antibody dependent cell mediated cytotoxicity; Cancer immunotherapy; Fc engineering; Human FCGR2B

Indexed keywords

ANTINEOPLASTIC AGENT; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOKINE ANTIBODY; DEATH RECEPTOR; DEATH RECEPTOR 5; DEATH RECEPTOR 5 ANTIBODY; FC RECEPTOR; FC RECEPTOR IIB; UNCLASSIFIED DRUG;

AGONIST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; ANTIBODIES; ANTIGENS, CD40; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEIN ENGINEERING; RECEPTORS, IGG; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84863594998     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1208698109     Document Type: Article

References (43)

1. Aggarwal BB (2003) Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 3:745-756.
2. Grewal IS (2009) Therapeutic Targets of the TNF Superfamily (Springer, New York, NY), pp 1-220.
3. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K (2001) The kiss of death: Promises and failures of death receptors and ligands in cancer therapy. Leukemia 15:1022-1032. (Pubitemid 32717270)
4. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ (2011) Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29:235-271.
5. Law CL, Grewal IS (2009) Therapeutic interventions targeting CD40L (CD154) and CD40: The opportunities and challenges. Adv Exp Med Biol 647:8-36.
6. Falschlehner C, Ganten TM, Koschny R, Schaefer U, Walczak H (2009) TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol 647:195-206.
7. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ (2007) Targeting death-inducing receptors in cancer therapy. Oncogene 26:3745-3757. (Pubitemid 46842709)
8. Takeda K, et al. (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199:437-448. (Pubitemid 38233828)
9. French RR, Chan HT, Tutt AL, Glennie MJ (1999) CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 5: 548-553. (Pubitemid 29220214)
10. + dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol 185: 532-541.
11. Demetri GD, et al. (2012) First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A phase I/II open-label and double-blind study. Eur J Cancer 48: 547-563.
12. Herbst RS, et al. (2010) A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 16:5883-5891.
13. Forero-Torres A, et al. (2010) Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 25:13-19.
14. Plummer R, et al. (2007) Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 13:6187-6194. (Pubitemid 350075080)
15. Wakelee HA, et al. (2010) Phase I and pharmacokinetic study of lexatumumab (HGSETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 21: 376-381.
16. Li F, Ravetch JV (2011) Inhibitory Fcγ receptor engagement drives adjuvant and antitumor activities of agonistic CD40 antibodies. Science 333:1030-1034.
17. White AL, et al. (2011) Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol 187:1754-1763.
18. Nimmerjahn F, Ravetch JV (2007) Antibodies, Fc receptors and cancer. Curr Opin Immunol 19:239-245. (Pubitemid 46356962)
19. Nimmerjahn F, Ravetch JV (2011) FcγRs in health and disease. Curr Top Microbiol Immunol 350:105-125.
20. Anthony RM, Wermeling F, Ravetch JV (2012) Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 1253:170-180.
21. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446. (Pubitemid 30208162)
22. Abboud N, et al. (2010) A requirement for FcγR in antibody-mediated bacterial toxin neutralization. J Exp Med 207:2395-2405.
23. Cohen ME, Xiao Y, Eisenberg RJ, Cohen GH, Isaacs SN (2011) Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors. PLoS ONE 6:e20597.
24. Vogt MR, et al. (2011) Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol 85:11567-11580.
25. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34-47.
26. Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV (1996) Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 379:346-349. (Pubitemid 26033077)
27. Fukuyama H, Nimmerjahn F, Ravetch JV (2005) The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol 6:99-106. (Pubitemid 40136701)
28. Xiang Z, et al. (2007) FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol 8:419-429. (Pubitemid 46745417)
29. Brownlie RJ, et al. (2008) Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J Exp Med 205:883-895. (Pubitemid 351549885)
30. Bolland S, Ravetch JV (2000) Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 13:277-285.
31. Desjarlais JR, Lazar GA (2011) Modulation of antibody effector function. Exp Cell Res 317:1278-1285.
32. Chu SY, et al. (2008) Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies. Mol Immunol 45:3926-3933.
33. Lazar GA, et al. (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103:4005-4010.
34. Takeda K, et al. (2008) Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci USA 105:10895-10900.
35. Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310:1510-1512. (Pubitemid 41746349)
36. Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV (2005) FcgammaRIV: A novel FcR with distinct IgG subclass specificity. Immunity 23:41-51. (Pubitemid 41019656)
37. Shields RL, et al. (2001) High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 276:6591-6604.
38. Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV (2012) Mouse model recapitulating human FcγR structural and functional diversity. Proc Natl Acad Sci USA 109: 6181-6186.
39. Wilson NS, et al. (2011) An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19:101-113.
40. Stefanescu RN, Olferiev M, Liu Y, Pricop L (2004) Inhibitory Fc gamma receptors: From gene to disease. J Clin Immunol 24:315-326. (Pubitemid 39005564)
41. Zhang M, et al. (2006) Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors. Blood 108:705-710. (Pubitemid 44061373)
42. Chuntharapai A, et al. (2001) Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166:4891-4898. (Pubitemid 32280698)
43. Xu Y, et al. (2003) Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: Implications for agonistic antibody-based therapeutics. J Immunol 171:562-568. (Pubitemid 36871362)